Item Number | Policy/Procedure | Date Posted | Comment Period Closed | Status | Document Links |
---|---|---|---|---|---|
2020-PHARM-257 | Thrombopoietin Agents PDL | 11/16/20 | 12/31/20 | Approved | Thrombopoietin Agents PDL |
2020-PHARM-256 | Sickle Cell Anemia PDL | 11/16/20 | 12/31/20 | Approved | Sickle Cell Anemia PDL |
2020-PHARM-255 | PPIs | 11/16/20 | 12/31/20 | Approved | PPIs |
2020-PHARM-254 | POS P and T January 2021 Posting | 11/16/20 | 12/31/20 | Approved | POS P and T January 2021 Posting |
2020-PHARM-253 | POS Thrombopoiesis Stimulating Proteins | 11/16/20 | 12/31/20 | Approved | POS Thrombopoiesis Stimulating Proteins |
2020-PHARM-252 | POS Sickle Cell Anemia Treatments | 11/16/20 | 12/31/20 | Approved | POS Sickle Cell Anemia Treatments |
2020-PHARM-251 | POS Movement Disorders VMAT2 Inhibitors | 11/16/20 | 12/31/20 | Approved | POS Movement Disorders VMAT2 Inhibitors |
2020-PHARM-250 | POS Methotrexate | 11/16/20 | 12/31/20 | Approved | POS Methotrexate |
2020-PHARM-249 | POS Immunomodulators Asthma | 11/16/20 | 12/31/20 | Approved | POS Immunomodulators Asthma |
2020-PHARM-248 | POS Immune Globulins | 11/16/20 | 12/31/20 | Approved | POS Immune Globulins |
2020-PHARM-247 | POS Idiopathic Pulmonary Fibrosis | 11/16/20 | 12/31/20 | Approved | POS Idiopathic Pulmonary Fibrosis |
2020-PHARM-246 | POS Enzyme Replacements | 11/16/20 | 12/31/20 | Approved | POS Enzyme Replacements |
2020-PHARM-245 | POS Botulinum Toxins | 11/16/20 | 12/31/20 | Approved | POS Botulinum Toxins |
2020-PHARM-244 | POS Antipsychotic Agents Oral | 11/16/20 | 12/31/20 | Approved | POS Antipsychotic Agents Oral |
2020-PHARM-243 | POS Anticonvulsants | 11/16/20 | 12/31/20 | Approved | POS Anticonvulsants |
2020-PHARM-242 | POS Anti-Allergens Oral | 11/16/20 | 12/31/20 | Approved | POS Anti-Allergens Oral |
2020-PHARM-241 | POS Anthelmintics | 11/16/20 | 12/31/20 | Approved | POS Anthelmintics |
2020-PHARM-240 | PDL 1.1.21 | 11/16/20 | 12/31/20 | Approved | PDL 1.1.21 |
2020-PHARM-239 | Otic Agents Antibiotics | 11/16/20 | 12/31/20 | Approved | Otic Agents Antibiotics |
2020-PHARM-238 | Ophthalmic Disorders Glaucoma Agents Intraocular Pressure Reducers | 11/16/20 | 12/31/20 | Approved | Ophthalmic Disorders Glaucoma Agents Intraocular Pressure Reducers |
2020-PHARM-237 | Oncology Agents Oral Renal Cell | 11/16/20 | 12/31/20 | Approved | Oncology Agents Oral Renal Cell |
2020-PHARM-236 | Movement Disorders VMAT2 Inhibitors | 11/16/20 | 12/31/20 | Approved | Movement Disorders VMAT2 Inhibitors |
2020-PHARM-235 | Methotrexate | 11/16/20 | 12/31/20 | Approved | Methotrexate |
2020-PHARM-234 | Immunomodulators Asthma | 11/16/20 | 12/31/20 | Approved | Immunomodulators Asthma |
2020-PHARM-233 | Immune Globulin | 11/16/20 | 12/31/20 | Approved | Immune Globulin |
2020-PHARM-232 | Idiopathic Pulmonary Fibrosis | 11/16/20 | 12/31/20 | Approved | Idiopathic Pulmonary Fibrosis |
2020-PHARM-231 | Enzyme Replacement Agents Gaucher's Disease | 11/16/20 | 12/31/20 | Approved | Enzyme Replacement Agents Gaucher's Disease |
2020-PHARM-230 | Dermatology-Atopic Dermatitis Immunomodulators | 11/16/20 | 12/31/20 | Approved | Dermatology-Atopic Dermatitis Immunomodulators |
2020-PHARM-229 | Botulinum Toxins | 11/16/20 | 12/31/20 | Approved | Botulinum Toxins |
2020-PHARM-228 | Asthma-COPD Inhaled Glucocorticoids | 11/16/20 | 12/31/20 | Approved | Asthma-COPD Inhaled Glucocorticoids |
2020-PHARM-227 | Anticonvulsants | 11/16/20 | 12/31/20 | Approved | Anticonvulsants |
2020-PHARM-226 | Anthelmintics | 11/16/20 | 12/31/20 | Approved | Anthelmintics |
2020-PHARM-225 | Allergen Extracts Oralair Palforzia | 11/16/20 | 12/31/20 | Approved | Allergen Extracts Oralair Palforzia |
2020-PHARM-224 | ADHD | 11/16/20 | 12/31/20 | Approved | ADHD |
2020-HB-PHARM-25 | Testosterone Injectables | 11/12/20 | 12/27/20 | Approved | Testosterone Injectables |
2020-HB-PHARM-24 | Tegsedi | 11/12/20 | 12/27/20 | Approved | Tegsedi |
2020-HB-PHARM-23 | Somatuline Depot | 11/12/20 | 12/27/20 | Approved | Somatuline Depot |
2020-HB-PHARM-22 | Selected GnRH Analogs | 11/12/20 | 12/27/20 | Approved | Selected GnRH Analogs |
2020-HB-PHARM-21 | Polivy | 11/12/20 | 12/27/20 | Approved | Polivy |
2020-HB-PHARM-20 | Onpattro | 11/12/20 | 12/27/20 | Approved | Onpattro |
2020-HB-PHARM-19 | Ocrevus | 11/12/20 | 12/27/20 | Approved | Ocrevus |
2020-HB-PHARM-18 | Lumoxiti | 11/12/20 | 12/27/20 | Approved | Lumoxiti |
2020-HB-PHARM-17 | Lumizyme | 11/12/20 | 12/27/20 | Approved | Lumizyme |
2020-HB-PHARM-16 | Libtayo | 11/12/20 | 12/27/20 | Approved | Libtayo |
2020-HB-PHARM-15 | Jevtana | 11/12/20 | 12/27/20 | Approved | Jevtana |
2020-HB-PHARM-14 | Implantable &ER Buprenorphine Products | 11/12/20 | 12/27/20 | Approved | Implantable &ER Buprenorphine Products |
2020-HB-PHARM-13 | Fabrazyme | 11/12/20 | 12/27/20 | Approved | Fabrazyme |
2020-HB-PHARM-12 | Evenity | 11/12/20 | 12/27/20 | Approved | Evenity |
2020-HB-PHARM-11 | Erythropoiesis Stimulating Agents | 11/12/20 | 12/27/20 | Approved | Erythropoiesis Stimulating Agents |
2020-HB-PHARM-10 | ERT for Gaucher’s Disease | 11/12/20 | 12/27/20 | Approved | ERT for Gaucher’s Disease |
2020-HB-PHARM-9 | Denosumab Agents | 11/12/20 | 12/27/20 | Approved | Denosumab Agents |
2020-HB-PHARM-8 | Brineura | 11/12/20 | 12/27/20 | Approved | Brineura |
2020-HB-PHARM-7 | Beta Interferons & Glatiramer Acetate | 11/12/20 | 12/27/20 | Approved | Beta Interferons & Glatiramer Acetate |
2020-HB-PHARM-6 | Benlysta | 11/12/20 | 12/27/20 | Approved | Benlysta |
2020-HB-PHARM-5.0 | Alpha-1 Proteinase Inhibitor Therapy | 11/12/20 | 12/27/20 | Approved | Alpha-1 Proteinase Inhibitor Therapy |
2020-ACLA-PHARM-5 | Diabetic Testing Supplies | 11/12/20 | 12/27/20 | Approved | Diabetic Testing Supplies |
2020-ACLA-818 | Prior Authorizations Update | 11/18/20 | 1/2/21 | Complete | Prior Authorizations Update |
2020-LDH-1 | LDH MCO Manual | 11/10/20 | 12/25/20 | Approved | LDH MCO Manual |
2020-HB-PHARM-5 | Avsola Medical Step Therapy | 11/4/20 | 12/18/20 | Approved | Avsola Medical Step Therapy |
2020-LHCC-PHARM-4 | Requests for Pharmacy Profiles | 10/30/20 | 12/13/20 | Approved | Requests for Pharmacy Profiles |
2020-LHCC-PHARM-3 | PBM Inquiry for Additional Information | 10/30/20 | 12/13/20 | Approved | PBM Inquiry for Additional Information |
2020-LHCC-PHARM-2 | Drug Utilization | 10/30/20 | 12/13/20 | Approved | Drug Utilization |
2020-HB-PHARM-4 | Anti VEGF Medical Step Therapy | 10/27/20 | 12/10/20 | Approved | Anti VEGF Medical Step Therapy |
2020-HB-PHARM-3 | Herceptin Bio Med Step Therapy | 10/26/20 | 12/9/20 | Approved | Herceptin Bio Med Step Therapy |
2020-PHARM-223 | Uterine Disorder Treatment | 10/26/20 | 12/9/20 | Approved | Uterine Disorder Treatment |
2020-PHARM-222 | Urology Incontinence Bladder Relaxant Preparations | 10/26/20 | 12/9/20 | Approved | Urology Incontinence Bladder Relaxant Preparations |
2020-PHARM-221 | Smoking Cessation Products | 10/26/20 | 12/9/20 | Approved | Smoking Cessation Products |
2020-PHARM-220 | Sinus Node Inhibitors | 10/26/20 | 12/9/20 | Approved | Sinus Node Inhibitors |
2020-PHARM-219 | Prostate Benign Prostatic Hyperplasia Treatment | 10/26/20 | 12/9/20 | Approved | Prostate Benign Prostatic Hyperplasia Treatment |
2020-PHARM-218 | Progestational Agents | 10/26/20 | 12/9/20 | Approved | Progestational Agents |
2020-PHARM-217 | Pituitary Suppressive Agents | 10/26/20 | 12/9/20 | Approved | Pituitary Suppressive Agents |
2020-PHARM-216 | Pediatric Multivitamins | 10/26/20 | 12/9/20 | Approved | Pediatric Multivitamins |
2020-PHARM-215 | Parkinsons Antiparkinson Agents Anticholinergic and Other | 10/26/20 | 12/9/20 | Approved | Parkinsons Antiparkinson Agents Anticholinergic and Other |
2020-PHARM-214 | Pain Management Skeletal Muscle Relaxants | 10/26/20 | 12/9/20 | Approved | Pain Management Skeletal Muscle Relaxants |
2020-PHARM-213 | Pain Management Neuropathic Pain | 10/26/20 | 12/9/20 | Approved | Pain Management Neuropathic Pain |
2020-PHARM-212 | Pain Management Narcotic Analgesics Short Acting | 10/26/20 | 12/9/20 | Approved | Pain Management Narcotic Analgesics Short Acting |
2020-PHARM-211 | Pain Management Narcotic Analgesics Long Acting | 10/26/20 | 12/9/20 | Approved | Pain Management Narcotic Analgesics Long Acting |
2020-PHARM-210 | Pain Management Cytokine and CAM Antagonists | 10/26/20 | 12/9/20 | Approved | Pain Management Cytokine and CAM Antagonists |
2020-PHARM-209 | Pain Management Antimigraine Agents Triptans | 10/26/20 | 12/9/20 | Approved | Pain Management Antimigraine Agents Triptans |
2020-PHARM-208 | Pain Management Antimigraine Agents Ergotamine | 10/26/20 | 12/9/20 | Approved | Pain Management Antimigraine Agents Ergotamine |
2020-PHARM-207 | Pain Management Antimigraine Agents CGRP Antagonists | 10/26/20 | 12/9/20 | Approved | Pain Management Antimigraine Agents CGRP Antagonists |
2020-PHARM-206 | Otic Agents Anti Infectives and Anesthetics | 10/26/20 | 12/9/20 | Approved | Otic Agents Anti Infectives and Anesthetics |
2020-PHARM-205 | Osteoporosis Bone Resorption Suppression Agents | 10/26/20 | 12/9/20 | Approved | Osteoporosis Bone Resorption Suppression Agents |
2020-PHARM-204 | Opiate Dependence Agents | 10/26/20 | 12/9/20 | Approved | Opiate Dependence Agents |
2020-PHARM-203 | Ophthalmic Disorders Glaucoma Agents Intraocular Pressure Reducers | 10/26/20 | 12/9/20 | Approved | Ophthalmic Disorders Glaucoma Agents Intraocular Pressure Reducers |
2020-PHARM-202 | Ophthalmic Disorders Anti-Inflammatory Immunomodulators | 10/26/20 | 12/9/20 | Approved | Ophthalmic Disorders Anti-Inflammatory Immunomodulators |
2020-PHARM-201 | Ophthalmic Disorders Anti-Inflammatories | 10/26/20 | 12/9/20 | Approved | Ophthalmic Disorders Anti-Inflammatories |
2020-PHARM-200 | Ophthalmic Disorders Antibiotic-Steroid Combinations | 10/26/20 | 12/9/20 | Approved | Ophthalmic Disorders Antibiotic-Steroid Combinations |
2020-PHARM-199 | Ophthalmic Disorders Allergic Conjunctivitis | 10/26/20 | 12/9/20 | Approved | Ophthalmic Disorders Allergic Conjunctivitis |
2020-PHARM-198 | Oncology Oral Skin | 10/26/20 | 12/9/20 | Approved | Oncology Oral Skin |
2020-PHARM-197 | Oncology Oral Renal Cell | 10/26/20 | 12/9/20 | Approved | Oncology Oral Renal Cell |
2020-PHARM-196 | Oncology Oral Prostate | 10/26/20 | 12/9/20 | Approved | Oncology Oral Prostate |
2020-PHARM-195 | Oncology Oral Other | 10/26/20 | 12/9/20 | Approved | Oncology Oral Other |
2020-PHARM-194 | Oncology Oral Lung | 10/26/20 | 12/9/20 | Approved | Oncology Oral Lung |
2020-PHARM-193 | Oncology Oral Hematologic | 10/26/20 | 12/9/20 | Approved | Oncology Oral Hematologic |
2020-PHARM-192 | Oncology Oral Breast | 10/26/20 | 12/9/20 | Approved | Oncology Oral Breast |
2020-PHARM-191 | Multiple Sclerosis Multiple Sclerosis Agents Immunomodulatory Agents | 10/26/20 | 12/9/20 | Approved | Multiple Sclerosis Multiple Sclerosis Agents Immunomodulatory Agents |
2020-PHARM-190 | Infectious Disorders Hepatitis C Agents Not Direct Acting Antiviral Agents | 10/26/20 | 12/9/20 | Approved | Infectious Disorders Hepatitis C Agents Not Direct Acting Antiviral Agents |
2020-PHARM-189 | Infectious Disorders Hepatitis C Agents Direct Acting Antiviral Agents | 10/26/20 | 12/9/20 | Approved | Infectious Disorders Hepatitis C Agents Direct Acting Antiviral Agents |
2020-PHARM-188 | Infectious Disorders Antibiotics Vaginal | 10/26/20 | 12/9/20 | Approved | Infectious Disorders Antibiotics Vaginal |
2020-PHARM-187 | Infectious Disorders Antibiotics Streptogramins | 10/26/20 | 12/9/20 | Approved | Infectious Disorders Antibiotics Streptogramins |
2020-PHARM-186 | Infectious Disorders Antibiotics Oxazolidinones | 10/26/20 | 12/9/20 | Approved | Infectious Disorders Antibiotics Oxazolidinones |
2020-PHARM-185 | Infectious Disorders Antibiotics Nitrofuran Derivatives | 10/26/20 | 12/9/20 | Approved | Infectious Disorders Antibiotics Nitrofuran Derivatives |
2020-PHARM-184 | Infectious Disorders Antibiotics Macrolides Ketolides | 10/26/20 | 12/9/20 | Approved | Infectious Disorders Antibiotics Macrolides Ketolides |
2020-PHARM-183 | Infectious Disorders Antibiotics Lincosamides | 10/26/20 | 12/9/20 | Approved | Infectious Disorders Antibiotics Lincosamides |
2020-PHARM-182 | Infectious Disorders Antibiotics Inhaled Antibiotics | 10/26/20 | 12/9/20 | Approved | Infectious Disorders Antibiotics Inhaled Antibiotics |
2020-PHARM-181 | Infectious Disorders Antibiotics Gastrointestinal Antibiotics | 10/26/20 | 12/9/20 | Approved | Infectious Disorders Antibiotics Gastrointestinal Antibiotics |
2020-PHARM-180 | Infectious Disorders Antibiotics Fluoroquinolones | 10/26/20 | 12/9/20 | Approved | Infectious Disorders Antibiotics Fluoroquinolones |
2020-PHARM-179 | Immunosuppressives Oral | 10/26/20 | 12/9/20 | Approved | Immunosuppressives Oral |
2020-PHARM-178 | Hemodialysis Phosphate Binders | 10/26/20 | 12/9/20 | Approved | Hemodialysis Phosphate Binders |
2020-PHARM-177 | Hematologic Agents Hematopoietic Agents Erythropoietins | 10/26/20 | 12/9/20 | Approved | Hematologic Agents Hematopoietic Agents Erythropoietins |
2020-PHARM-176 | Heart Disease Hyperlipidemia Vasodilators Coronary | 10/26/20 | 12/9/20 | Approved | Heart Disease Hyperlipidemia Vasodilators Coronary |
2020-PHARM-175 | Heart Disease Hyperlipidemia Sympatholytics | 10/26/20 | 12/9/20 | Approved | Heart Disease Hyperlipidemia Sympatholytics |
2020-PHARM-174 | Heart Disease Hyperlipidemia Statins and Statin Combination Agents | 10/26/20 | 12/9/20 | Approved | Heart Disease Hyperlipidemia Statins and Statin Combination Agents |
2020-PHARM-173 | Heart Disease Hyperlipidemia Pulmonary Arterial Hypertension | 10/26/20 | 12/9/20 | Approved | Heart Disease Hyperlipidemia Pulmonary Arterial Hypertension |
2020-PHARM-172 | Heart Disease Hyperlipidemia Lipotropics Other | 10/26/20 | 12/9/20 | Approved | Heart Disease Hyperlipidemia Lipotropics Other |
2020-PHARM-171 | Heart Disease Hyperlipidemia Hypertension Calcium Channel Blockers | 10/26/20 | 12/9/20 | Approved | Heart Disease Hyperlipidemia Hypertension Calcium Channel Blockers |
2020-PHARM-170 | Heart Disease Hyperlipidemia Hypertension Beta Blocker Agents | 10/26/20 | 12/9/20 | Approved | Heart Disease Hyperlipidemia Hypertension Beta Blocker Agents |
2020-PHARM-169 | Heart Disease Hyperlipidemia Hypertension Angiotensin Modulators Calcium Channel Blockers Combinations | 10/26/20 | 12/9/20 | Approved | Heart Disease Hyperlipidemia Hypertension Angiotensin Modulators Calcium Channel Blockers Combinations |
2020-PHARM-168 | Heart Disease Hyperlipidemia Hypertension ACE Inhibitors and Direct Renin Inhibitors | 10/26/20 | 12/9/20 | Approved | Heart Disease Hyperlipidemia Hypertension ACE Inhibitors and Direct Renin Inhibitors |
2020-PHARM-167 | Heart Disease Hyperlipidemia Anticoagulants Platelet Aggregation Inhibitors | 10/23/20 | 12/6/20 | Pending | Heart Disease Hyperlipidemia Anticoagulants Platelet Aggregation Inhibitors |
2020-PHARM-166 | Heart Disease Hyperlipidemia Anticoagulants | 10/23/20 | 12/6/20 | Pending | Heart Disease Hyperlipidemia Anticoagulants |
2020-PHARM-165 | H Pylori Treatment | 10/23/20 | 12/6/20 | Pending | H Pylori Treatment |
2020-PHARM-164 | Growth Deficiency Growth Hormones | 10/23/20 | 12/6/20 | Pending | Growth Deficiency Growth Hormones |
2020-PHARM-163 | Gout Agents Antihyperuricemics | 10/23/20 | 12/6/20 | Pending | Gout Agents Antihyperuricemics |
2020-PHARM-162 | Glucocorticoids Oral | 10/23/20 | 12/6/20 | Pending | Glucocorticoids Oral |
2020-PHARM-161 | GI Motility Chronic | 10/23/20 | 12/6/20 | Pending | GI Motility Chronic |
2020-PHARM-160 | Epinephrine Self Injected | 10/23/20 | 12/6/20 | Pending | Epinephrine Self Injected |
2020-PHARM-159 | Digestive Disorders Ulcerative Colitis Agents | 10/23/20 | 12/6/20 | Pending | Digestive Disorders Ulcerative Colitis Agents |
2020-PHARM-158 | Digestive Disorders Proton Pump Inhibitors | 10/23/20 | 12/6/20 | Pending | Digestive Disorders Proton Pump Inhibitors |
2020-PHARM-157 | Digestive Disorders Pancreatic Enzymes | 10/23/20 | 12/6/20 | Pending | Digestive Disorders Pancreatic Enzymes |
2020-PHARM-156 | Digestive Disorders Histamine II Receptor Blockers | 10/23/20 | 12/6/20 | Pending | Digestive Disorders Histamine II Receptor Blockers |
2020-PHARM-155 | Digestive Disorders Bile Acid Salts | 10/23/20 | 12/6/20 | Pending | Digestive Disorders Bile Acid Salts |
2020-PHARM-154 | Digestive Disorders Antiemetic Antivertigo Agents | 10/23/20 | 12/6/20 | Pending | Digestive Disorders Antiemetic Antivertigo Agents |
2020-PHARM-153 | Diabetes Metformins | 10/23/20 | 12/6/20 | Pending | Diabetes Metformins |
2020-PHARM-152 | Diabetes Hypoglycemics Thiazolidinediones | 10/23/20 | 12/6/20 | Pending | Diabetes Hypoglycemics Thiazolidinediones |
2020-PHARM-151 | Diabetes Hypoglycemics Sulfonylureas | 10/23/20 | 12/6/20 | Pending | Diabetes Hypoglycemics Sulfonylureas |
2020-PHARM-150 | Diabetes Hypoglycemics Sodium Glucose Co Transporter 2 Inhibitors | 10/23/20 | 12/6/20 | Pending | Diabetes Hypoglycemics Sodium Glucose Co Transporter 2 Inhibitors |
2020-PHARM-149 | Diabetes Hypoglycemics Meglitinides | 10/23/20 | 12/6/20 | Pending | Diabetes Hypoglycemics Meglitinides |
2020-PHARM-148 | Diabetes Hypoglycemics Insulins and Related Agents | 10/23/20 | 12/6/20 | Pending | Diabetes Hypoglycemics Insulins and Related Agents |
2020-PHARM-147 | Diabetes Hypoglycemics Incretin Mimetics Enhancers | 10/23/20 | 12/6/20 | Pending | Diabetes Hypoglycemics Incretin Mimetics Enhancers |
2020-PHARM-146 | Diabetes Alpha Glucosidase Inhibitors | 10/23/20 | 12/6/20 | Pending | Diabetes Alpha Glucosidase Inhibitors |
2020-PHARM-145 | Dermatology Steroids Topical Medium Potency | 10/23/20 | 12/6/20 | Pending | Dermatology Steroids Topical Medium Potency |
2020-PHARM-144 | Dermatology Steroids Topical Low Potency | 10/23/20 | 12/6/20 | Pending | Dermatology Steroids Topical Low Potency |
2020-PHARM-143 | Dermatology Steroids Topical High Potency | 10/23/20 | 12/6/20 | Pending | Dermatology Steroids Topical High Potency |
2020-PHARM-142 | Dermatology Immunomodulators Topical | 10/23/20 | 12/6/20 | Pending | Dermatology Immunomodulators Topical |
2020-PHARM-141 | Dermatology Emollients | 10/23/20 | 12/6/20 | Pending | Dermatology Emollients |
2020-PHARM-140 | Dermatology Atopic Dermatitis Immunomodulators | 10/23/20 | 12/6/20 | Pending | Dermatology Atopic Dermatitis Immunomodulators |
2020-PHARM-139 | Dermatology Antiviral Agents Topical | 10/23/20 | 12/6/20 | Pending | Dermatology Antiviral Agents Topical |
2020-PHARM-138 | Dermatology Antipsoriatics Topical | 10/23/20 | 12/6/20 | Pending | Dermatology Antipsoriatics Topical |
2020-PHARM-137 | Dermatology Antipsoriatics Oral | 10/23/20 | 12/6/20 | Pending | Dermatology Antipsoriatics Oral |
2020-PHARM-136 | Dermatology Antiparasitic Agents Topical | 10/23/20 | 12/6/20 | Pending | Dermatology Antiparasitic Agents Topical |
2020-PHARM-135 | Cystic Fibrosis Oral | 10/23/20 | 12/6/20 | Pending | Cystic Fibrosis Oral |
2020-PHARM-134 | Colony Stimulating Factors | 10/23/20 | 12/6/20 | Pending | Colony Stimulating Factors |
2020-PHARM-133 | Asthma COPD Leukotriene Modifiers | 10/23/20 | 12/6/20 | Pending | Asthma COPD Leukotriene Modifiers |
2020-PHARM-132 | Asthma COPD Glucocorticoids Inhalation | 10/22/20 | 12/5/20 | Approved | Asthma COPD Glucocorticoids Inhalation |
2020-PHARM-131 | Asthma COPD Bronchodilator Beta Adrenergic Oral Agents | 10/22/20 | 12/5/20 | Approved | Asthma COPD Bronchodilator Beta Adrenergic Oral Agents |
2020-PHARM-130 | Asthma COPD Bronchodilator Beta Adrenergic Inhalation Agents | 10/22/20 | 12/5/20 | Approved | Asthma COPD Bronchodilator Beta Adrenergic Inhalation Agents |
2020-PHARM-129 | Asthma COPD Bronchodilator Anticholinergics COPD Oral | 10/22/20 | 12/5/20 | Approved | Asthma COPD Bronchodilator Anticholinergics COPD Oral |
2020-PHARM-128 | Asthma COPD Bronchodilator Anticholinergics COPD Inhalation | 10/22/20 | 12/5/20 | Approved | Asthma COPD Bronchodilator Anticholinergics COPD Inhalation |
2020-PHARM-127 | Antivirals Oral | 10/22/20 | 12/5/20 | Approved | Antivirals Oral |
2020-PHARM-126 | Androgenic Agents | 10/22/20 | 12/5/20 | Approved | Androgenic Agents |
2020-PHARM-125 | Alzheimers Agents | 10/22/20 | 12/5/20 | Approved | Alzheimers Agents |
2020-PHARM-124 | Allergy Rhinitis Agents Nasal | 10/22/20 | 12/5/20 | Approved | Allergy Rhinitis Agents Nasal |
2020-PHARM-123 | Allergy Antihistamines Minimally Sedating | 10/22/20 | 12/5/20 | Approved | Allergy Antihistamines Minimally Sedating |
2020-PHARM-122 | Vyondys | 10/22/20 | 12/5/20 | Approved | Vyondys |
2020-PHARM-121 | Spinraza Form | 10/22/20 | 12/5/20 | Approved | Spinraza Form |
2020-PHARM-120 | Spinraza Criteria | 10/22/20 | 12/5/20 | Approved | Spinraza Criteria |
2020-PHARM-119 | Selected Anti Infective Anti Fungal and Corticosteroid Quantity Limits Plus Criteria | 10/22/20 | 12/5/20 | Approved | Selected Anti Infective Anti Fungal and Corticosteroid Quantity Limits Plus Criteria |
2020-PHARM-118 | POS DUR January 2021 Posting Revised | 10/22/20 | 12/5/20 | Approved | POS DUR January 2021 Posting Revised |
2020-PHARM-117 | POS Sedative Hypnotics | 10/22/20 | 12/5/20 | Approved | POS Sedative Hypnotics |
2020-PHARM-116 | POS Pain Management Nonsteroidal Anti Inflammatory Drugs | 10/22/20 | 12/5/20 | Approved | POS Pain Management Nonsteroidal Anti Inflammatory Drugs |
2020-PHARM-115 | POS Otic Agents Antibiotics | 10/22/20 | 12/5/20 | Approved | POS Otic Agents Antibiotics |
2020-PHARM-114 | POS Opthalmic Disorders Antibiotics | 10/22/20 | 12/5/20 | Approved | POS Opthalmic Disorders Antibiotics |
2020-PHARM-113 | POS Infectious Disorders Antifungals Oral | 10/22/20 | 12/5/20 | Approved | POS Infectious Disorders Antifungals Oral |
2020-PHARM-112 | POS Infectious Disorders Antibiotics Tetracyclines | 10/22/20 | 12/5/20 | Approved | POS Infectious Disorders Antibiotics Tetracyclines |
2020-PHARM-111 | POS Infectious Disorders Antibiotics Cephalosporin and Related Antibiotics | 10/22/20 | 12/5/20 | Approved | POS Infectious Disorders Antibiotics Cephalosporin and Related Antibiotics |
2020-PHARM-110 | POS Hemophilia Treatment | 10/22/20 | 12/5/20 | Approved | POS Hemophilia Treatment |
2020-PHARM-109 | POS Document for October DUR | 10/22/20 | 12/5/20 | Approved | POS Document for October DUR |
2020-PHARM-108 | POS Dermatology Steriods Topical Very High Potency | 10/22/20 | 12/5/20 | Approved | POS Dermatology Steriods Topical Very High Potency |
2020-PHARM-107 | POS Dermatology Antifungals Topical | 10/22/20 | 12/5/20 | Approved | POS Dermatology Antifungals Topical |
2020-PHARM-106 | POS Dermatology Antibiotics Topical | 10/22/20 | 12/5/20 | Approved | POS Dermatology Antibiotics Topical |
2020-PHARM-105 | POS Depression Selective Serotonin Reuptake Inhibitors | 10/22/20 | 12/5/20 | Approved | POS Depression Selective Serotonin Reuptake Inhibitors |
2020-PHARM-104 | POS Depression Antidepressants Other | 10/22/20 | 12/5/20 | Approved | POS Depression Antidepressants Other |
2020-PHARM-103 | POS Anxiolytics | 10/22/20 | 12/5/20 | Approved | POS Anxiolytics |
2020-PHARM-102 | POS Antipsychotic Agents Oral | 10/22/20 | 12/5/20 | Approved | POS Antipsychotic Agents Oral |
2020-PHARM-101 | POS Antipsychotic Agents Injectable Agents | 10/22/20 | 12/5/20 | Approved | POS Antipsychotic Agents Injectable Agents |
2020-PHARM-100 | POS ADD-ADHD Stimulants and Related Agents | 10/22/20 | 12/5/20 | Approved | POS ADD-ADHD Stimulants and Related Agents |
2020-PHARM-99 | POS Acne Agents | 10/22/20 | 12/5/20 | Approved | POS Acne Agents |
2020-PHARM-98 | PDL 7-1-20 for 10-7-20 Diabetic Supplies | 10/22/20 | 12/5/20 | Approved | PDL 7-1-20 for 10-7-20 Diabetic Supplies |
2020-PHARM-97 | Pain Management Non Steriodal AntiInflammatory Agents | 10/22/20 | 12/5/20 | Approved | Pain Management Non Steriodal AntiInflammatory Agents |
2020-PHARM-96 | Other Behavioral Health Under 7 | 10/22/20 | 12/5/20 | Approved | Other Behavioral Health Under 7 |
2020-PHARM-95 | Nocdurna POS | 10/22/20 | 12/5/20 | Approved | Nocdurna POS |
2020-PHARM-94 | Medically Necessary Criteria | 10/22/20 | 12/5/20 | Approved | Medically Necessary Criteria |
2020-PHARM-93 | Louisiana Medicaid ICD-10 Chart with October DUR Updates redline | 10/22/20 | 12/5/20 | Approved | Louisiana Medicaid ICD-10 Chart with October DUR Updates redline |
2020-PHARM-92 | Immune Globulin Criteria | 10/22/20 | 12/5/20 | Approved | Immune Globulin Criteria |
2020-PHARM-91 | Exondys | 10/22/20 | 12/5/20 | Approved | Exondys |
2020-PHARM-90 | Evrysdi | 10/22/20 | 12/5/20 | Approved | Evrysdi |
2020-PHARM-89 | Epidiolex Criteria | 10/22/20 | 12/5/20 | Approved | Epidiolex Criteria |
2020-PHARM-88 | Enzyme Replacement Therapy Diagnosis Code and TD Edits | 10/22/20 | 12/5/20 | Approved | Enzyme Replacement Therapy Diagnosis Code and TD Edits |
2020-PHARM-87 | Diabetes Strips Lancets Quantity Limit | 10/22/20 | 12/5/20 | Approved | Diabetes Strips Lancets Quantity Limit |
2020-PHARM-86 | Depression Antidepressants SSRIs | 10/22/20 | 12/5/20 | Approved | Depression Antidepressants SSRIs |
2020-PHARM-85 | Depression Antidepressants Other | 10/22/20 | 12/5/20 | Approved | Depression Antidepressants Other |
2020-PHARM-84 | Cytokine and CAM Antagonists | 10/22/20 | 12/5/20 | Approved | Cytokine and CAM Antagonists |
2020-PHARM-83 | Botulinum Toxins Diagnosis Code and Quantity Limits | 10/22/20 | 12/5/20 | Approved | Botulinum Toxins Diagnosis Code and Quantity Limits |
2020-PHARM-82 | Anxiolytics | 10/22/20 | 12/5/20 | Approved | Anxiolytics |
2020-PHARM-81 | Antipsychotics | 10/22/20 | 12/5/20 | Approved | Antipsychotics |
2020-PHARM-80 | Allergen Extracts | 10/22/20 | 12/5/20 | Approved | Allergen Extracts |
2020-PHARM-79 | ADHD | 10/22/20 | 12/5/20 | Approved | ADHD |
2020-HB-PHARM-2 | Avastin Biosimilars Sed Step Therapy Notice | 10/22/20 | 12/5/20 | Approved | Avastin Biosimilars Sed Step Therapy Notice |
2020-UHC-PHARM-26 | Benlysta | 10/21/20 | 12/4/20 | Approved | Benlysta |
2020-UHC-PHARM-25 | Trogarzo | 10/21/20 | 12/4/20 | Approved | Trogarzo |
2020-UHC-PHARM-24 | Testosterone | 10/21/20 | 12/4/20 | Approved | Testosterone |
2020-UHC-PHARM-23 | Radicava | 10/16/20 | 11/30/20 | Approved | Radicava |
2020-UHC-PHARM-22 | Reblozyl | 10/16/20 | 11/30/20 | Approved | Reblozyl |
2020-UHC-PHARM-21 | Parsabiv | 10/16/20 | 11/30/20 | Approved | Parsabiv |
2020-UHC-PHARM-20 | Immune Globulins | 10/16/20 | 11/30/20 | Approved | Immune Globulins |
2020-UHC-PHARM-19 | Botulinum Toxins | 10/16/20 | 11/30/20 | Approved | Botulinum Toxins |
2020-UHC-PHARM-18 | Rituxan | 10/16/20 | 11/30/20 | Approved | Rituxan |
2020-UHC-PHARM-17 | Somatostatin Analogs | 10/16/20 | 11/30/20 | Approved | Somatostatin Analogs |
2020-UHC-PHARM-16 | Buprenorphine | 10/16/20 | 11/30/20 | Approved | Buprenorphine |
2020-UHC-PHARM-15 | Gaucher Disease | 10/13/20 | 11/27/20 | Approved | Gaucher Disease |
2020-UHC-PHARM-14 | Vyepti | 10/13/20 | 11/27/20 | Approved | Vyepti |
2020-UHC-PHARM-13 | Enzyme Replacement Therapy | 10/13/20 | 11/27/20 | Approved | Enzyme Replacement Therapy |
2020-UHC-PHARM-12 | Tepezza | 10/13/20 | 11/27/20 | Approved | Tepezza |
2020-UHC-PHARM-11 | Onpattro | 10/13/20 | 11/27/20 | Approved | Onpattro |
2020-UHC-PHARM-10 | Complement Inhibitors | 10/13/20 | 11/27/20 | Approved | Complement Inhibitors |
2020-UHC-PHARM-9 | IV Iron Replacement Therapy | 10/13/20 | 11/27/20 | Approved | IV Iron Replacement Therapy |
2020-UHC-PHARM-8 | Denosumab | 10/13/20 | 11/27/20 | Approved | Denosumab |
2020-UHC-PHARM-7 | Brineura | 10/13/20 | 11/27/20 | Approved | Brineura |
2020-UHC-PHARM-6 | Crysvita | 10/13/20 | 11/27/20 | Approved | Crysvita |
2020-UHC-PHARM-5 | Krystexxa | 10/13/20 | 11/27/20 | Approved | Krystexxa |
2020-UHC-PHARM-4 | Sodium Hyaluronate | 10/13/20 | 11/27/20 | Approved | Sodium Hyaluronate |
2020-LHCC-PHARM-1 | Pharmacy Prior Authorization and Medical Necessity | 9/30/20 | 11/14/20 | Approved | Pharmacy Prior Authorization and Medical Necessity |
2020-UHC-PHARM-1 | Scenesse | 9/28/20 | 11/12/20 | Approved | Scenesse |
2020-UHC-PHARM-2 | Uplizna | 9/28/20 | 11/12/20 | Approved | Uplizna |
2020-UHC-PHARM-3 | Viltepso | 9/28/20 | 11/12/20 | Approved | Viltepso |
2020-ACLA-PHARM-4 | Specialty Drugs PA Criteria | 9/15/20 | 10/30/20 | Approved | Specialty Drugs PA Criteria |
2020-ACLA-PHARM-3 | Oncology Drugs PA Criteria | 9/8/20 | 10/24/20 | Approved | Oncology Drugs PA Criteria |
2020-ACLA-PHARM-1 | Remdesivir | 9/1/20 | 10/16/20 | Approved | Remdesivir |
2020-ACLA-PHARM-2 | Diabetic Testing Supplies | 9/1/20 | 10/16/20 | Approved | Diabetic Testing Supplies |
2020-LHCC-814 | Crisis Intervention Policy | 8/28/20 | 10/12/20 | Approved | Crisis Intervention Policy |
2020-LHCC-817 | Vitamin D Testing Policy | 8/28/20 | 10/12/20 | Approved | Vitamin D Testing Policy |
2020-ABH-PHARM-2 | Compounds | 8/25/20 | 10/9/20 | Complete | Compounds |
2020-ABH-PHARM-1 | Quantity Level Limit | 8/19/20 | 10/3/20 | Approved | Quantity Level Limit |
2020-HBL-816 | Vitamin D Policy | 8/18/20 | 10/2/20 | Approved | Vitamin D Policy |
2020-ACLA-815 | Vitamin D Policy | 8/14/20 | 9/28/20 | Approved | Vitamin D Policy |
2020-ABH-813 | Vitamin D Policy | 8/14/20 | 9/28/20 | Approved | Vitamin D Policy |
2020-HPA-3 | HPA: Tobacco Cessation for Pregnant Women | 8/11/20 | 9/25/20 | Complete | HPA: Tobacco Cessation for Pregnant Women |
2020-IB-2 | IB: Tobacco Cessation for Pregnant Women | 8/11/20 | 9/25/20 | Complete | IB: Tobacco Cessation for Pregnant Women |
2020-UHC-812 | Vitamin D Policy | 8/7/20 | 9/21/20 | Approved | Vitamin D Policy |
2020-SCG-3 | Tracking of Evidence Based Practices (EBP) | 8/6/20 | 9/20/20 | Complete | MCO SCG July 2020 pg. 16-17 |
2020-PHARM-78 | Asthma COPD Bronchodilator Anticholinergics Inhalation | 7/31/20 | 9/14/20 | Approved | Asthma COPD Bronchodilator Anticholinergics Inhalation |
2020-PHARM-77 | Cytokineand CAM Antagonists | 7/31/20 | 9/14/20 | Approved | Cytokineand CAM Antagonists |
2020-PHARM-76 | Dermatology Atopic Dermatitis Immunomodulators | 7/31/20 | 9/14/20 | Approved | Dermatology Atopic Dermatitis Immunomodulators |
2020-PHARM-75 | Diabetes Hypoglycemics Incretin Mimetics Enhancers | 7/31/20 | 9/14/20 | Approved | Diabetes Hypoglycemics Incretin Mimetics Enhancers |
2020-PHARM-74 | Esbriet | 7/31/20 | 9/14/20 | Approved | Esbriet |
2020-PHARM-73 | Fetroja | 7/31/20 | 9/14/20 | Approved | Fetroja |
2020-PHARM-72 | Givlaari | 7/31/20 | 9/14/20 | Approved | Givlaari |
2020-PHARM-71 | Hepatitis C DAA | 7/31/20 | 9/14/20 | Approved | Hepatitis C DAA |
2020-PHARM-70 | Infectious Disorders Hepatitis C Agents Direct Acting Antiviral Agents | 7/31/20 | 9/14/20 | Approved | Infectious Disorders Hepatitis C Agents Direct Acting Antiviral Agents |
2020-PHARM-69 | Koselugo | 7/31/20 | 9/14/20 | Approved | Koselugo |
2020-PHARM-68 | Ofev | 7/31/20 | 9/14/20 | Approved | Ofev |
2020-PHARM-67 | Oxbryta | 7/31/20 | 9/14/20 | Approved | Oxbryta |
2020-PHARM-66 | POS DUR October 2020 | 7/31/20 | 9/14/20 | Approved | POS DUR October 2020 |
2020-PHARM-65 | Sedative Hypnotics | 7/31/20 | 9/14/20 | Approved | Sedative Hypnotics |
2020-PHARM-64 | Tikosyn | 7/31/20 | 9/14/20 | Approved | Tikosyn |
2020-PHARM-63 | VMAT2 Inhibitors | 7/31/20 | 9/14/20 | Approved | VMAT2 Inhibitors |
2020-PHARM-62 | Xenleta | 7/31/20 | 9/14/20 | Approved | Xenleta |
2020-HBL-366 | Out-of-Area, Out-of-Network Care | 7/24/20 | 9/7/20 | Approved | Out-of-Area, Out-of-Network Care |
2020-HBL-542.1 2020-HBL-542.2 | Anesthesia Services for Interventional Pain Management Procedures and Clinical Guidelines | 7/24/20 | 9/7/20 | Completed | Anesthesia Services for Interventional Pain Management Procedures Clinical Guidelines |
2020-UHC-564 | Benlysta | 7/24/20 | 9/7/20 | Approved | Benlysta |
2020-UHC-565 | Crysvita | 7/24/20 | 9/7/20 | Approved | Crysvita |
2020-UHC-567 | Maximum Dosage | 7/24/20 | 9/7/20 | Approved | Maximum Dosage |
2020-UHC-568 | Ocrevus | 7/24/20 | 9/7/20 | Approved | Ocrevus |
2020-UHC-569 | Off Label Unproven | 7/24/20 | 9/7/20 | Approved | Off Label Unproven |
2020-UHC-572 | Reblozyl | 7/24/20 | 9/7/20 | Approved | Reblozyl |
2020-UHC-574 | Testosterone Replacement | 7/24/20 | 9/7/20 | Approved | Testosterone Replacement |
2020-LHCC-610 | Authorization Error Correction Process | 7/24/20 | 9/7/20 | Completed | Authorization Error Correction Process |
2020-LHCC-636 | Authorization for Second Clinical Opinions | 7/24/20 | 9/7/20 | Completed | Authorization for Second Clinical Opinions |
2020-LHCC-682 | Active Procedures in Physical Medicine | 7/24/20 | 9/7/20 | Approved | Active Procedures in Physical Medicine |
2020-LHCC-683 | Chiro Infant Care Policy | 7/24/20 | 9/7/20 | Approved | Chiro Infant Care Policy |
2020-LHCC-684 | Chiro Infant Care Policy | 7/24/20 | 9/7/20 | Approved | Chiro Infant Care Policy |
2020-LHCC-685 | Experimental, Unproven, or Investigational Services | 7/24/20 | 9/7/20 | Approved | Experimental, Unproven, or Investigational Services |
2020-HBL-318 | Clinical Information for Utilization Review | 7/16/20 | 8/30/20 | Approved | Clinical Information for Utilization Review |
2020-HBL-328 | Pre-Certification of Requested Services | 7/16/20 | 8/30/20 | Approved | Pre-Certification of Requested Services |
2020-UHC-535 | Nat'l Drug Code (NDC) Requirement Policy | 7/16/20 | 8/30/20 | Approved | Nat'l Drug Code (NDC) Requirement Policy |
2020-ACLA-538 | PCP Assignment | 7/16/20 | 8/30/20 | Approved | PCP Assignment |
2020-HBL-588 | Retrospective Review | 7/16/20 | 8/30/20 | Approved | Retrospective Review |
2020-LHCC-609 | Court Ordered Services Louisiana PP | 7/16/20 | 8/30/20 | Approved | Court Ordered Services Louisiana PP |
2020-HBL-677 | SPOT AIM Rehab Transition Bulletin | 7/16/20 | 8/30/20 | Approved | SPOT AIM Rehab Transition Bulletin |
2020-HB-PHARM-1 | Louisiana Compound Coverage | 7/21/20 | 9/4/20 | Approved | Louisiana Compound Coverage |
2020-HBL-316 | Associates Performing Utilization Review | 7/9/20 | 8/23/20 | Approved | Associates Performing Utilization Review |
2020-HBL-576 | AIM Musculoskeletal Prog Clinical Appropriateness Guidelines | 7/9/20 | 8/23/20 | Approved | AIM Musculoskeletal Prog Clinical Appropriateness Guidelines |
2020-LHCC-329 | Adverse Determinations | 7/9/20 | 8/23/20 | Approved | Adverse Determinations |
2020-LHCC-429 | UM Program Description | 7/9/20 | 8/23/20 | Approved | UM Program Description |
2020-LHCC-498 | Mental Health Rehab MNC Policy | 7/9/20 | 8/23/20 | Approved | Mental Health Rehab MNC Policy |
2020-LHCC-532 | Appropriate UM Professionals | 7/9/20 | 8/23/20 | Approved | Appropriate UM Professionals |
2020-LHCC-607 | Inpatient Leveling of Care WP | 7/9/20 | 8/23/20 | Completed | Inpatient Leveling of Care WP |
2020-UHC-557 | Transcranial Magnetic Stimulation | 7/9/20 | 8/23/20 | Approved | Transcranial Magnetic Stimulation |
2020-UHC-558 | Knee Replacement Surgery (Arthroplasty), Total and Partial | 7/9/20 | 8/23/20 | Approved | Knee Replacement Surgery (Arthroplasty), Total and Partial |
2020-UHC-559 | Implantable Beta-Emitting Microspheres | 7/9/20 | 8/23/20 | Approved | Implantable Beta-Emitting Microspheres |
2020-UHC-560 | Home Hemodialysis | 7/9/20 | 8/23/20 | Approved | Home Hemodialysis |
2020-UHC-561 | Cognitive Rehabilitation | 7/9/20 | 8/23/20 | Approved | Cognitive Rehabilitation |
2020-HBL-602.1 | Medical drug Clinical Criteria updates | 7/2/20 | 8/16/20 | Approved | Medical drug Clinical Criteria updates |
2020-HBL-602.2 | Faslodex Criteria | 7/2/20 | 8/16/20 | Approved | Faslodex Criteria |
2020-HBL-602.3 | Gazyva Criteria | 7/2/20 | 8/16/20 | Approved | Gazyva Criteria |
2020-HBL-602.4 | Immunoglobulins Criteria | 7/2/20 | 8/16/20 | Approved | Immunoglobulins Criteria |
2020-HBL-602.5 | Intravitreal Corticosteroid Implants Criteria | 7/2/20 | 8/16/20 | Approved | Intravitreal Corticosteroid Implants Criteria |
2020-HBL-602.6 | Keytruda Criteria | 7/2/20 | 8/16/20 | Approved | Keytruda Criteria |
2020-HBL-602.7 | Gonadotropin Releasing Hormone Analogs for the Treatment of Non-Oncologic Indications Criteria | 7/2/20 | 8/16/20 | Approved | Gonadotropin Releasing Hormone Analogs for the Treatment of Non-Oncologic Indications Criteria |
2020-LHCC-505 | New Follow-Up After Hospitalization Policy | 7/2/20 | 8/16/20 | Approved | New Follow-Up After Hospitalization Policy |
2020-LHCC-611 | Appeals Process | 7/2/20 | 8/16/20 | Completed | Appeals Process |
2020-UHC-563 | Actemra Criteria | 7/2/20 | 8/16/20 | Approved | Actemra Criteria |
2020-UHC-570 | Orencia Criteria | 7/2/20 | 8/16/20 | Approved | Orencia Criteria |
2020-LHCC-331 | Provider Manual | 6/25/20 | 8/10/20 | Approved | Provider Manual |
2020-UHC-585 | Chelation Therapy | 6/25/20 | 8/10/20 | Approved | Chelation Therapy |
2020-PHARM-61 | Hepatitis C DAA | 6/22/20 | 8/7/20 | Approved | Hepatitis C DAA |
2020-ACLA-325 | Provider Manual | 6/18/20 | 8/3/20 | Approved | Provider Manual |
2020-HBL-115 | Multiple Bilateral Article and Policy | 6/18/20 | 8/3/20 | Approved | Multiple Bilateral Article and Policy 1Multiple Bilateral Article and Policy 2 |
2020-HBL-120 | Psychiatris Res Trmt Fac PRTF Gde, Med Gde and Withdrawal Gde | 6/18/20 | 8/3/20 | Approved | Psychiatris Res Trmt Fac PRTF Gde Med Gde Withdrawal Gde |
2020-HBL-250 | Provider Manual | 6/18/20 | 8/3/20 | Denied | Provider Manual |
2020-UHC-324 | Provider Manual | 6/18/20 | 8/3/20 | Approved | Provider Manual |
2020-UHC-513 | Epidural Steroid and Facet Injections for Spinal Pain (for Louisiana Only) | 6/18/20 | 8/3/20 | Approved | Epidural Steroid and Facet Injections for Spinal Pain (for Louisiana Only) |
2020-UHC-516 | Reimbursement Policy: Obstetrical Services Policy | 6/18/20 | 8/3/20 | Approved | Reimbursement Policy: Obstetrical Services Policy |
2020-UHC-518 | Reimbursement Policy: Global Days Policy | 6/18/20 | 8/3/20 | Approved | Reimbursement Policy: Global Days Policy |
2020-UHC-519 | Reimbursement Policy: Vaccines for Children | 6/18/20 | 8/3/20 | Approved | Reimbursement Policy: Vaccines for Children |
2020-UHC-529 | AIM Advanced Imaging Clinical Appropr. Guidelines | 6/18/20 | 8/3/20 | Approved | AIM Advanced Imaging Clinical Appropr. Guidelines 1 AIM Advanced Imaging Clinical Appropr. Guidelines 2 AIM Advanced Imaging Clinical Appropr. Guidelines 3 AIM Advanced Imaging Clinical Appropr. Guidelines 4 |
2020-UHC-531 | AIM Advanced Imaging Clinical Appropr. Guidelines | 6/18/20 | 8/3/20 | Approved | AIM Advanced Imaging Clinical Appropr. Guidelines |
2020-UHC-534 | Add On Codes Policy | 6/18/20 | 8/3/20 | Approved | Add On Codes Policy 1 Add On Codes Policy 2 |
2020-PHARM-60 | Multiple Sclerosis Agents for August 2020 | 6/15/20 | 7/30/20 | Approved | Multiple Sclerosis Agents |
2020-UHC-511 | Manipulation Under Anesthesia | 6/10/20 | 7/25/20 | Approved | Manipulation Under Anesthesia |
2020-UHC-512 | Glaucoma Surgical Treatment | 6/10/20 | 7/25/20 | Approved | Glaucoma Surgical Treatment |
2020-ABH-114 | Limitations on Abortions | 6/9/20 | 7/24/20 | Approved | Limitations on Abortions |
2020-ABH-496 | Community Psychiatric Support and Treatment (CPST) and Psychosocial Rehabilitation (PSR) Services | 6/9/20 | 7/24/20 | Approved | Community Psychiatric Support and Treatment (CPST) and Psychosocial Rehabilitation (PSR) Services |
2020-ACLA-368 | Split Surgery Care | 6/9/20 | 7/24/20 | Approved | Split Surgery Care |
2020-ACLA-380 | Assistant Surgery Care | 6/9/20 | 7/24/20 | Approved | Assistant Surgery Care |
2020-ACLA-381 | Co-Surgery | 6/9/20 | 7/24/20 | Approved | Co-Surgery |
2020-ACLA-484 | Prior Authorization Requirements | 6/9/20 | 7/24/20 | Completed | Prior Authorization Requirements |
2020-ACLA-495 | Anesthesia Services for Gastrointestinal Endoscopy | 6/9/20 | 7/24/20 | Approved | Anesthesia Services for Gastrointestinal Endoscopy |
2020-ACLA-507 | Site of Care Medical Pharmacy | 6/9/20 | 7/24/20 | Approved | Site of Care Medical Pharmacy |
2020-ACLA-508 | Outpatient Surgical Procedures | 6/9/20 | 7/24/20 | Approved | Outpatient Surgical Procedures |
2020-HBL-257 | Pediatric Day Health Care and Personal Care Services | 6/9/20 | 7/24/20 | Approved | Pediatric Day Health Care and Personal Care Services |
2020-HBL-319 | Unlisted Unspecified Misc Codes Newsletter | 6/9/20 | 7/24/20 | Completed | Unlisted Unspecified Misc Codes Newsletter |
2020-HBL-327 | Distinct Procedural | 6/9/20 | 7/24/20 | Completed | Distinct Procedural |
2020-HBL-359 | Justice Involved Case Management | 6/9/20 | 7/24/20 | Approved | Justice Involved Case Management |
2020-HBL-360 | Durable Medical Equipment | 6/9/20 | 7/24/20 | Approved | Durable Medical Equipment |
2020-HBL-415 | Case Management Face to Face Intervention | 6/9/20 | 7/24/20 | Approved | Case Management Face to Face Intervention |
2020-HBL-416 | Unlisted Unspecified Misc Codes Policy | 6/9/20 | 7/24/20 | Completed | Unlisted Unspecified Misc Codes Policy |
2020-HBL-485 | Standing Referral | 6/9/20 | 7/24/20 | Completed | Standing Referral |
2020-HBL-515 | Louisiana Provider Payment Suspension (Hold) | 6/9/20 | 7/24/20 | Completed | Louisiana Provider Payment Suspension (Hold) |
2020-LHCC-314 | Infusion Therapy Site Of Care Optimization | 6/9/20 | 7/24/20 | Approved | Infusion Therapy Site Of Care Optimization |
2020-LHCC-315 | Testing Select GU Conditions | 6/9/20 | 7/24/20 | Approved | Testing Select GU Conditions |
2020-LHCC-334 | Disease Management Policies | 6/9/20 | 7/24/20 | Approved | Disease Management Policies |
2020-LHCC-335 | Quality Program Description | 6/9/20 | 7/24/20 | Approved | Quality Program Description |
2020-LHCC-336 | Care Management Program Description | 6/9/20 | 7/24/20 | Completed | Care Management Program Description |
2020-LHCC-338 | Perinatal Substance Use Disorder Care Management Program | 6/9/20 | 7/24/20 | Approved | Perinatal Substance Use Disorder Care Management Program |
2020-LHCC-342 | Medical Record Review | 6/9/20 | 7/24/20 | Completed | Medical Record Review |
2020-LHCC-419 | Provider Termination | 6/9/20 | 7/24/20 | Completed | Provider Termination |
2020-LHCC-421 | Provider Relations Demographic Provider Roster Affiliation Verification | 6/9/20 | 7/24/20 | Completed | Provider Relations Demographic Provider Roster Affiliation Verification |
2020-LHCC-422 | Network Development and Management | 6/9/20 | 7/24/20 | Completed | Network Development and Management |
2020-LHCC-423 | EPSDT | 6/9/20 | 7/24/20 | Approved | EPSDT |
2020-LHCC-424 | PASRR | 6/9/20 | 7/24/20 | Approved | PASRR |
2020-LHCC-426 | Adverse Incidents | 6/9/20 | 7/24/20 | Approved | Adverse Incidents |
2020-LHCC-430 | Covered Benefits and Services | 6/9/20 | 7/24/20 | Approved | Covered Benefits and Services |
2020-LHCC-431 | Monitoring Utilization | 6/9/20 | 7/24/20 | Approved | Monitoring Utilization |
2020-LHCC-432 | Psychiatric Treatment Facility | 6/9/20 | 7/24/20 | Approved | Psychiatric Treatment Facility |
2020-LHCC-497 | Emergency Services Policy | 6/9/20 | 7/24/20 | Completed | Emergency Services Policy |
2020-LHCC-499 | Retrospective Review For Services Requiring Authorizations | 6/9/20 | 7/24/20 | Completed | Retrospective Review For Services Requiring Authorizations |
2020-LHCC-500 | Policy, Procedure and Job Description Guidelines Policy | 6/9/20 | 7/24/20 | Completed | Policy, Procedure and Job Description Guidelines Policy |
2020-LHCC-501 | Access to Non-Emergency Transportation policy | 6/9/20 | 7/24/20 | Approved | Access to Non-Emergency Transportation policy |
2020-LHCC-502 | Clinical Information and Documentation Policy | 6/9/20 | 7/24/20 | Completed | Clinical Information and Documentation Policy |
2020-LHCC-503 | Evaluation of the Accessibility of services | 6/9/20 | 7/24/20 | Completed | Evaluation of the Accessibility of services |
2020-LHCC-504 | Quality PIPs policy | 6/9/20 | 7/24/20 | Approved | Quality PIPs policy |
2020-LHCC-525 | Remote Field Staff Quarterly HIPPA and Equipment audit policy | 6/9/20 | 7/24/20 | Completed | Remote Field Staff Quarterly HIPPA and Equipment audit policy |
2020-LHCC-526 | TruCare Standards for Documentation policy | 6/9/20 | 7/24/20 | Completed | TruCare Standards for Documentation policy |
2020-LHCC-527 | Organizational Cultural Competency policy | 6/9/20 | 7/24/20 | Completed | Organizational Cultural Competency policy |
2020-LHCC-528 | Public Records Request policy | 6/9/20 | 7/24/20 | Completed | Public Records Request policy |
2020-UHC-374 | Electrical and Ultrasound Bone Growth Stimulators | 6/9/20 | 7/24/20 | Completed | Electrical and Ultrasound Bone Growth Stimulators |
2020-UHC-382 | Benlysta (Belimumab) | 6/9/20 | 7/24/20 | Completed | Benlysta (Belimumab) |
2020-UHC-383 | Oncology Medication Clinical Coverage | 6/9/20 | 7/24/20 | Completed | Oncology Medication Clinical Coverage |
2020-UHC-384 | Intravenous Iron Replacement Therapy (Feraheme & Injectafer) | 6/9/20 | 7/24/20 | Completed | Intravenous Iron Replacement Therapy (Feraheme & Injectafer) |
2020-UHC-385 | Ketalar (Ketamine) and Spravato (Esketamine) | 6/9/20 | 7/24/20 | Completed | Ketalar (Ketamine) and Spravato (Esketamine) |
2020-UHC-386 | Luxturna (Voretigene Neparvovec-rzyl) | 6/9/20 | 7/24/20 | Completed | Luxturna (Voretigene Neparvovec-rzyl) |
2020-UHC-387 | Review At Launch For New To Market Medications | 6/9/20 | 7/24/20 | Completed | Review At Launch For New To Market Medications |
2020-UHC-389 | Somatostatin Analogs | 6/9/20 | 7/24/20 | Completed | Somatostatin Analogs |
2020-UHC-390 | Vyondys 53 (Golodirsen) | 6/9/20 | 7/24/20 | Completed | Vyondys 53 (Golodirsen) |
2020-UHC-391 | Zulresso (Brexanolone) | 6/9/20 | 7/24/20 | Completed | Zulresso (Brexanolone) |
2020-UHC-392 | Alpha1-Proteinase Inhibitors | 6/9/20 | 7/24/20 | Completed | Alpha1-Proteinase Inhibitors |
2020-UHC-393 | Botulinum Toxins A and B | 6/9/20 | 7/24/20 | Completed | Botulinum Toxins A and B |
2020-UHC-394 | Denosumab (Prolia & Xgeva) | 6/9/20 | 7/24/20 | Completed | Denosumab (Prolia & Xgeva) |
2020-UHC-396 | Exondys 51 (Eteplirsen) | 6/9/20 | 7/24/20 | Approved | Exondys 51 (Eteplirsen) |
2020-UHC-397 | Ilaris (Canakinumab) | 6/9/20 | 7/24/20 | Completed | Ilaris (Canakinumab) |
2020-UHC-398 | Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease | 6/9/20 | 7/24/20 | Completed | Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease |
2020-UHC-399 | Buprenorphine (Probuphine & Sublocade) | 6/9/20 | 7/24/20 | Approved | Buprenorphine (Probuphine & Sublocade) |
2020-UHC-400 | Compliment Inhibitors (SOLIRIS & ULTOMIRIS) | 6/9/20 | 7/24/20 | Completed | Compliment Inhibitors (SOLIRIS & ULTOMIRIS) |
2020-UHC-401 | Crysvita (BUROSUMAB-TWZA) | 6/9/20 | 7/24/20 | Completed | Crysvita (BUROSUMAB-TWZA) |
2020-UHC-402 | Denied Drug Codes - Pharmacy Benefit Drugs | 6/9/20 | 7/24/20 | Approved | Denied Drug Codes - Pharmacy Benefit Drugs |
2020-UHC-403 | Enzyme Replacement Therapy | 6/9/20 | 7/24/20 | Completed | Enzyme Replacement Therapy |
2020-UHC-404 | Erythropoiesis Stimulating Agents | 6/9/20 | 7/24/20 | Completed | Erythropoiesis Stimulating Agents |
2020-UHC-405 | Gonadatropin Releasing Hormones | 6/9/20 | 7/24/20 | Approved | Gonadatropin Releasing Hormones |
2020-UHC-406 | Immune Globulin (IVIG and SCIG) | 6/9/20 | 7/24/20 | Approved | Immune Globulin (IVIG and SCIG) |
2020-UHC-407 | Krystexxa | 6/9/20 | 7/24/20 | Completed | Krystexxa |
2020-UHC-408 | Maximum Dosage | 6/9/20 | 7/24/20 | Approved | Maximum Dosage |
2020-UHC-409 | Opthalmologic VEGF Inhibitors | 6/9/20 | 7/24/20 | Approved | Opthalmologic VEGF Inhibitors |
2020-UHC-410 | Sodium Hyaluronate | 6/9/20 | 7/24/20 | Approved | Sodium Hyaluronate |
2020-UHC-411 | Tysabri | 6/9/20 | 7/24/20 | Approved | Tysabri |
2020-UHC-412 | WBC-CSF | 6/9/20 | 7/24/20 | Approved | WBC-CSF |
2020-UHC-413 | Addendum to BH Utilization Management | 6/9/20 | 7/24/20 | Approved | Addendum to BH Utilization Management |
2020-UHC-417 | Prior Authorization Requirements | 6/9/20 | 7/24/20 | Completed | Prior Authorization Requirements |
2020-UHC-479 | Cardiac Event Monitoring -Annual CPT/HCPCS Code Updates and MCG | 6/9/20 | 7/24/20 | Completed | Cardiac Event Monitoring -Annual CPT/HCPCS Code Updates and MCG |
2020-UHC-481 | CPT/HCPCS Updates Prosthetic Devices | 6/9/20 | 7/24/20 | Approved | CPT/HCPCS Updates Prosthetic Devices |
2020-UHC-482 | CPT / HCPCS Updates Molecular Oncology Testing | 6/9/20 | 7/24/20 | Approved | CPT / HCPCS Updates Molecular Oncology Testing |
2020-UHC-483 | CPT/HCPCS Updates Genetic Testing for Hereditary Cancer | 6/9/20 | 7/24/20 | Approved | CPT/HCPCS Updates Genetic Testing for Hereditary Cancer |
2020-UHC-493 | Surgical Treatment for Spine Pain | 6/9/20 | 7/24/20 | Completed | Surgical Treatment for Spine Pain |
2020-UHC-509 | Breast Reconstruction Post Mastectomy | 6/9/20 | 7/24/20 | Approved | Breast Reconstruction Post Mastectomy |
2020-UHC-510 | COLLAGEN CROSSLINKS AND BIOCHEMICAL MARKERS OF BONE TURNOVER | 6/9/20 | 7/24/20 | Approved | COLLAGEN CROSSLINKS AND BIOCHEMICAL MARKERS OF BONE TURNOVER |
2020-UHC-520 | Panniculectomy Body Contouring Procedures | 6/9/20 | 7/24/20 | Approved | Panniculectomy Body Contouring Procedures |
2020-UHC-521 | Gastrointestinal Motility Disorders Diagnosis and Treatment | 6/9/20 | 7/24/20 | Approved | Gastrointestinal Motility Disorders Diagnosis and Treatment |
2020-UHC-523 | Intrauterine Fetal Surgery | 6/9/20 | 7/24/20 | Approved | Intrauterine Fetal Surgery |
2020-UHC-524 | DME Repairs and Replacements | 6/9/20 | 7/24/20 | Approved | DME Repairs and Replacements |
2020-UHC-530 | Reimbursement Policy: DRUG TESTING POLICY | 6/9/20 | 7/24/20 | Approved | Reimbursement Policy: DRUG TESTING POLICY |
2020-PHARM-59 | Acne Agents | 5/29/20 | 7/13/20 | Approved | Acne Agents |
2020-PHARM-58 | Acne Criteria | 5/29/20 | 7/13/20 | Approved | Acne Criteria |
2020-PHARM-57 | Adakveo | 5/29/20 | 7/13/20 | Approved | Adakveo |
2020-PHARM-56 | CGRP Antagonists | 5/29/20 | 7/13/20 | Approved | CGRP Antagonists |
2020-PHARM-55 | Colony Stimulating Factors | 5/29/20 | 7/13/20 | Approved | Colony Stimulating Factors |
2020-PHARM-54 | Diabetes Hypoglycemics Incretin Mimetics Enhancers | 5/29/20 | 7/13/20 | Approved | Diabetes Hypoglycemics Incretin Mimetics Enhancers |
2020-PHARM-53 | Egrifta | 5/29/20 | 7/13/20 | Approved | Egrifta |
2020-PHARM-52 | Keveyis | 5/29/20 | 7/13/20 | Approved | Keveyis |
2020-PHARM-51 | Multiple Sclerosis Agents Immunomodulatory Agents | 5/29/20 | 7/13/20 | Approved | Multiple Sclerosis Agents Immunomodulatory Agents |
2020-PHARM-50 | Multiple Sclerosis Agents | 5/29/20 | 7/13/20 | Approved | Multiple Sclerosis Agents |
2020-PHARM-49 | Other Behavioral Health Under 6 | 5/29/20 | 7/13/20 | Approved | Other Behavioral Health Under 6 |
2020-PHARM-48 | Otrexup Rasuvo | 5/29/20 | 7/13/20 | Approved | Otrexup Rasuvo |
2020-PHARM-47 | Pain Management Antimigraine Agents CGRP Antagonists | 5/29/20 | 7/13/20 | Approved | Pain Management Antimigraine Agents CGRP Antagonists |
2020-PHARM-46 | Pain Management Antimigraine Agentss Triptans 5/27/20 | 5/29/20 | 7/13/20 | Approved | Pain Management Antimigraine Agentss Triptans 5/27/20 |
2020-PHARM-45 | Pain Management Antimigraine Agents Triptans 5/26/20 | 5/29/20 | 7/13/20 | Approved | Pain Management Antimigraine Agents Triptans 5/26/20 |
2020-PHARM-44 | POS Document for May DUR | 5/29/20 | 7/13/20 | Approved | POS Document for May DUR |
2020-PHARM-43 | Ranexa | 5/29/20 | 7/13/20 | Approved | Ranexa |
Medicaid Managed Care Policies & Procedures Archive (2020)
"Policy or procedure" shall mean a requirement governing the administration of managed care organizations specific to billing guidelines, medical management and utilization review guidelines, case management guidelines, claims processing guidelines and edits, grievance and appeals procedures and process, other guidelines or manuals containing pertinent information related to operations and pre-processing claims, and core benefits and services.
Below are items previously posted for public comment: